AHArmagan Hazar

Armagan Hazar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Armagan Hazar has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Eosinophilic endotype as a predictor of NIV success in COPD exacerbation with acute respiratory failure

    by Abdurrahman Yılmaz, Sinem Güngör, Eylem Tunçay, Elif Yılmaz, Esra Usta Bülbül, Birsen Ocaklı, Fatma Armağan Hazar, Zühal Karakurt

    Background: Many studies have been conducted on the impact of eosinophilia in chronic obstructive pulmonary disease (COPD) patients; however, there is a lack of clear data showing the relationship with the success of non-invasive ventilation (NIV) in exacerbations. This study aimed to investigate whether the eosinophilic endotype predicts the response to NIV in patients with COPD exacerbations presenting with acute respiratory failure. We also sought to determine if eosinophil cutoff values of ≥ 2% and ≥ 0.34 cells/L, previously used to define eosinophilic exacerbations, are effective in predicting NIV success. Methods: A retrospective analysis was conducted on 1142 patients admitted to the emergency room (ER) of a tertiary chest diseases hospital for COPD exacerbation with acute respiratory failure, who received NIV. Data were obtained from the electronic data management system and ER triage. Patients were categorized into two groups: NIV success and NIV failure. NIV success was defined as discharge from the ER or admission to the ward, while NIV failure was defined as intubation, death, or admission to the intensive care unit (ICU). Differences between the groups were analyzed. Results: Of the 1142 patients, 816 (71%) were male, with a mean age of 66 years (range: 40–80). A total of 932 (82%) patients were in the NIV success group, while 210 (18%) were in the NIV failure group. The eosinophilic endotype, defined by a cutoff of ≥ 2%, was observed in 33% of NIV success patients and 25% of NIV failure patients ( p < 0.05). An absolute eosinophil count of ≥ 0.34 cells/L was found in 13% ( n = 120) of NIV success patients and 9% ( n = 19) of NIV failure patients ( p > 0.05). Conclusion: Our study suggests that NIV success in COPD exacerbation is more likely when the eosinophil percentage is ≥ 2%. This may be attributed to the fact that exacerbations in the eosinophilic endotype are generally less severe and respond better to corticosteroid therapy.

  • The utility of neutrophil-to-lymphocyte ratio determined at initial diagnosis in predicting disease stage and discriminating between active and stable disease in patients with sarcoidosis: a cross-sectional study

    by Sumeyye Alparslan Bekir, Esin Sonkaya, Fatma Ozbaki, Selma Aydogan Eroglu, Lale Sertcelik, Dildar Duman, Murat Kavas, Meltem Agca, Ipek Erdem, Ipek Ozmen, et al.

    To evaluate the utility of neutrophil–lymphocyte ratio (NLR) determined at initial diagnosis in predicting advanced disease stage and discriminating between active and stable disease in sarcoidosis...


  • Open Access

    Antibiotic treatment outcomes in community-acquired pneumonia

    by Aykut Çi̇lLi̇, Abdullah Sayiner, Burcu Çelenk, Ayşın ŞAKAR COŞKUN, Oğuz Kilinç, Armağan HAZAR, Anıl AKTAŞ SAMUR, Sezai Taşbakan, Grant W. Waterer, Yavuz Havlucu, et al.

    Background/aim: The optimal empiric antibiotic regimen for patients with community-acquired pneumonia (CAP) remains unclear. This study aimed to evaluate the clinical cure rate, mortality, and length of stay among patients hospitalized with community-acquired pneumonia in nonintensive care unit (ICU) wards and treated with a beta-lactam, beta-lactam and macrolide combination, or a fluoroquinolone. Materials and methods: This prospective cohort study was perfbrined using standardized web-based database sheets from January 2009 to September 2013 in nine tertiary care hospitals in Turkey. Results: Six hundred and twenty-one consecutive patients were enrolled. A pathogen was identified in 78 (12.6%) patients. The most frequently isolated bacteria were S. pneumoniae (21.8%) and P. aeruginosa (19.2%). The clinical cure rate and length of stay were not different among patients treated with beta-lactam, beta-lactam and macrolide combination, and fluoroquinolone. Forty-seven patients (9.2%) died during the hospitalization period. There was no difference in survival among the three treatment groups. Conclusion: In patients admitted to non-ICU hospital wards for CAP, there was no difference in clinical outcomes between beta-lactam, beta-lactam and macrolide combination, and fluoroquinolone regimens.